-
Mashup Score: 0CTLA-4 Inhibitors for Patients With PD-L1–Negative/PD-L1 - 14 hour(s) ago
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 13
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Christian Rolfo, MD, PhD, argued that perioperative immunotherapy should not be used to treat patients with lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Updates in CLL Treatment: 5-Year Off-Treatment Analyses From the CLL14 and MURANO Trials - 2 day(s) ago
This video presents the 5-year off-treatment analyses from the CLL14 and MURANO studies.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Cabozantinib Shows Promising Activity Among Patients With Progressive, Unresectable Metastatic Phaeochromocytomas and Paragangliomas - 6 day(s) ago
According to results from the phase 2 Natalie trial, cabozantinib showed promising clinical activity among patients with progressive, unresectable metastatic phaeochromocytomas and paragangliomas.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
According to interim analysis results from the phase 3 KEYNOTE-564 trial, adjuvant pembrolizumab significantly improved overall survival compared to placebo among patients with clear-cell renal cell carcinoma at increased risk of recurrence after surgical resection.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0FDA Approves Tisotumab Vedotin for Patients With Recurrent or Metastatic Cervical Cancer - 7 day(s) ago
Based on results from the phase 3 innovaTV 301 trial, the FDA has approved tisotumab vedotin for patients with recurrent or metastatic cervical cancer who experienced disease progression on or after systemic treatment.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0
Results from the phase 2 NRG Oncology/GOG Study 279 found that gemcitabine plus cisplatin concurrently administered with intensity-modulated radiation therapy improved complete pathologic response among patients with locally advanced, unresectable vulvar squamous cell carcinoma.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet-
According to Neil Horowitz, MD, and coauthors, "compared with historic results, the addition of gemcitabine to cisplatin once per week given concurrently with [intensity-modulated RT] significantly improved the [pCR]." Learn more: https://t.co/aSZNAGXIiY #medtwitter #onctwitter https://t.co/4A9aDPWVOZ
-
-
Mashup Score: 2
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Jamie Chaft, MD, argued in favor of both pre- and post-operative immunotherapy in the treatment of lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1Supremacy of Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer - 11 day(s) ago
At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Mini-Hyper-CVD Plus Venetoclax Yields Safety and Activity Among Patients With Heavily Pretreated R/R ALL - 13 day(s) ago
According to a phase 1/2 trial, combining mini-hyper-CVD low-intensity chemotherapy with venetoclax yielded safety and activity among patients with heavily pretreated R/R acute lymphoblastic leukemia.
Source: www.hmpgloballearningnetwork.comCategories: General Medicine News, Onc News and JournalsTweet
At #GDULC, Koosha Paydary, MD, MPH, MSc, argued that CTLA-4 inhibitors should not be used to treat patients with PD-L1 negative or PD-L1 <1% lung cancers. Learn more: https://t.co/YD6PYoMbqC #medtwitter #onctwitter https://t.co/N5jvII2Nc3